Naoto Ueno
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Naoto T. Ueno | |
|---|---|
| Born | March 29, 1964 Kyoto, Japan |
| Academic background | |
| Doctoral advisor | Mien-Chie Hung |
| Academic work | |
| Institutions | University of Hawaiʻi Cancer Center |
Naoto T. Ueno (born March 1964, Kyoto, Japan[1]) is Director of the University of Hawaiʻi (Mānoa) Cancer Center,[2] one of the 74 NCI National Cancer Centers.[3] He was formerly Professor of Medicine at The University of Texas MD Anderson Cancer Center, and was also a visiting professor with the Keio University.[4] Ueno's research is in the area of inflammatory breast cancer and the molecular mechanism of metastasis and tumorigenicity.
He is a breast medical oncologist who specializes in inflammatory, triple-negative, and metastatic breast cancer. He is best known for his preclinical development of E1A gene therapy and multiple preclinical developments, which led to novel clinical trials related to inflammatory and triple-negative breast cancer.
Ueno moved from Texas to the University of Hawaiʻi to be director in December 2022.[5] He also practices at Queen's Medical Center and Kapiolani Chidren and Women's Hospital.
Dr. Ueno studies cancer metastasis, MAPK/EGFR pathways, and cancer microenvironment. He previously was the executive director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic and Section Chief of the Translational Breast Cancer Research at the Department of Breast Medical Oncology at the Anderson Cancr Center.
He is the founder of the Japan TeamOnclogy Program and CancerX.[6]
Awards
[edit]- 1995-1996 Clinical Fellow Research Award, MD Anderson Cancer Center
- 1996 Cancer Research Achievement Award, MD Anderson Cancer Center
- 1996 Houston Endowment, Jesse H. Jones Fellowship in Cancer Education
- 1996 Outstanding Achievement in Cancer Research Award, Pharmacia and Upjohn
- 1998 American Association Cancer Research-Glaxo Wellcome Oncology Clinical Research Scholar Award for Promising Translation or Clinical Research, Glaxo Wellcome
- 2008 6th Robert M. Chamberlain Distinguished Mentor Award Nomination (Top Three Finalist), MD Anderson
- 2011 Amgen Basic Research Award, 2nd Prize for Mentoring, MDACC
- 2013 Regent's Outstanding Teaching Award, University of Texas
- 2013 Bradley Stuart Beller Special Merit ASCO Merit Award for Hiroko Masusda, MD, PhD (Mentee)
- 2018 Rune for the Cure Foundation. Unknown Hero Award.
References
[edit]- ^ Piana, Ronald (January 25, 2024). "New Director of the University of Hawaii Cancer Center, Naoto T. Ueno, MD, PhD, FACP, Is Also a Two-Time Cancer Survivor". The ASCO Post. Retrieved October 14, 2024.
- ^ "Naoto T. Ueno announced as new UH Cancer Center director | University of Hawaiʻi System News". October 14, 2022. Retrieved October 14, 2024.
- ^ "Find an NCI-Designated Cancer Center - NCI". www.cancer.gov. September 7, 2023. Retrieved October 14, 2024.
- ^ "Naoto Tada Ueno, M.D., Ph.D., F.A.C.P. - Breast Medical Oncology - Faculty - MD Anderson Cancer Center". University of Texas MD Anderson Cancer Center. Archived from the original on January 5, 2012. Retrieved December 25, 2011.
- ^ "New UH Cancer Center director shares vision for future | University of Hawaiʻi System News". January 9, 2023.
- ^ Stromberg, Sandi. "MD Anderson takes its 'normal' to Japan". MD Anderson Cancer Center.
| International | |
|---|---|
| National | |
